Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Breast Cancer Patients”

757 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 757 results

Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT06954480
What this trial is testing

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Queen Mary University of London 140
Testing effectiveness (Phase 2)Study completedNCT04758780
What this trial is testing

Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Institut Cancerologie de l'Ouest 12
Testing effectiveness (Phase 2)UnknownNCT02681562
What this trial is testing

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Istituti Ospitalieri di Cremona 45
Early research (Phase 1)UnknownNCT05498597
What this trial is testing

AMT-151 in Patients With Selected Advanced Solid Tumours

Who this might be right for
Advanced Solid TumorAdvanced CancerAdvanced Carcinoma+16 more
Multitude Therapeutics Inc. 30
Early research (Phase 1)Study completedNCT03289962
What this trial is testing

Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Who this might be right for
MelanomaNon-Small Cell Lung CancerBladder Cancer+5 more
Genentech, Inc. 272
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05953168
What this trial is testing

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 69
Testing effectiveness (Phase 2)Looking for participantsNCT06845319
What this trial is testing

Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients

Who this might be right for
Triple Negative Breast Cancer
Medical University of South Carolina 43
Testing effectiveness (Phase 2)UnknownNCT05266937
What this trial is testing

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Who this might be right for
Metastatic Breast CancerTriple Negative Breast CancerPD-L1 Gene Mutation
Consorzio Oncotech 49
Early research (Phase 1)WithdrawnNCT02427581
What this trial is testing

Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Who this might be right for
Triple Negative Breast CancerTriple Negative Breast NeoplasmsTriple-Negative Breast Cancer
Washington University School of Medicine
Testing effectiveness (Phase 2)Looking for participantsNCT05770531
What this trial is testing

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Who this might be right for
Metastatic HER2-Negative Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma
Vanderbilt-Ingram Cancer Center 160
Testing effectiveness (Phase 2)Study completedNCT03057600
What this trial is testing

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast Cancer
Calithera Biosciences, Inc 52
Early research (Phase 1)Study completedNCT01920061
What this trial is testing

PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Who this might be right for
Neoplasm
Pfizer 110
Not applicableStudy completedNCT02670577
What this trial is testing

Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry

Who this might be right for
Breast Cancer
Agendia 481
Not applicableNot Yet RecruitingNCT06684054
What this trial is testing

Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC

Who this might be right for
T-Cell DysfunctionChemotherapy EffectAdverse Events
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 30
Early research (Phase 1)Study completedNCT02014337
What this trial is testing

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Who this might be right for
Breast CancerOvarian Epithelial Cancer RecurrentSarcoma+4 more
Corcept Therapeutics 37
Not applicableLooking for participantsNCT07260188
What this trial is testing

Organoids From Breast Cancer Patients Treated With Neoadjuvant Therapy

Who this might be right for
Invasive Breast Cancer
Istituti Clinici Scientifici Maugeri SpA 240
Testing effectiveness (Phase 2)Study completedNCT01091454
What this trial is testing

Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Alliance for Clinical Trials in Oncology 48
Testing effectiveness (Phase 2)UnknownNCT03692689
What this trial is testing

Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer

Who this might be right for
Triple Negative Breast Neoplasms
Sinocelltech Ltd. 30
Large-scale testing (Phase 3)Active Not RecruitingNCT03997123
What this trial is testing

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Who this might be right for
Triple Negative Breast Neoplasms
AstraZeneca 923
Load More Results